The research combines experimental wet lab-based approaches in human cancer models, C. elegans, and yeast with computational/ bioinformatics-based research.
This group investigates the molecular and cellular mechanisms underlying the ageing process, and in particular cancer as a major age-related disease. In terms of cancer research, there is a focus on the investigation of anti-cancer therapies including the discovery and development of novel anti-cancer drugs, drug targets, and biomarkers. As part of this research, the school hosts the Resistant Cancer Cell Line (RCCL) collection, the largest collection worldwide of models of acquired cancer drug resistance comprising over 1,300 human cancer cell lines across 15 cancer entities and 67 anti-cancer drugs (both targeted and cytotoxic) https://www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html.
The group has received funding from research funders including the BBSRC, MRC, Cancer Research UK, Human Frontiers Science Program, Kent Cancer Trust, Breast Cancer Kent, the Royal Society, the Rosetrees Trust, and the Bill & Melinda Gates Foundation and works in collaboration with a range of industrial partners.
Find out more about the research facilities in the University of Kent School of Biosciences
Phone: +44 (0)1227 823743
School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ